Martingale Asset Management L P C4 Therapeutics, Inc. Transaction History

Martingale Asset Management L P

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$3.1 - $9.02 $20,844 - $60,650	6,724 Added 20.57%	39,420 $123,000
Q4 2022 Feb 13, 2023	BUY	$5.42 - $10.24 $8,130 - $15,360	1,500 Added 4.81%	32,696 $192,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $14,189 - $22,564	1,767 Added 6.0%	31,196 $274,000
Q2 2022 Aug 11, 2022	BUY	$5.06 - $26.46 $148,910 - $778,691	29,429 New	29,429 $221,000
Q1 2022 May 12, 2022	SELL	$19.99 - $33.23 $322,018 - $535,302	-16,109 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$29.39 - $46.86 $473,443 - $754,867	16,109 New	16,109 $518,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $178M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Martingale Asset Management L P, based on Form 13F filings with the SEC.

Stay updated on Martingale Asset Management L P with notifications on news.